Literature DB >> 31387182

Low dose of chronic ethanol exposure in adult zebrafish induces hepatic steatosis and injury.

Ki-Hoon Park1, Seok-Hyung Kim2.   

Abstract

Chronic alcohol consumption is a major cause of chronic liver disease worldwide. Adult zebrafish have emerged as a new vertebrate model of alcoholic liver disease. In previous research, a high dose of chronic ethanol treatment induced characteristic features of steatosis and hepatic injury in adult zebrafish, yet the ethanol concentration in that study was significantly higher than the lethal dose in humans. In the current study, we examined whether a low dose of chronic ethanol exposure in adult zebrafish induced the metabolic and pathological features seen in alcoholic liver disease. We found that chronic ethanol treatment at 0.2% ethanol (v/v) concentration for 4 weeks induced a significant elevation of serum glucose and triacylglycerol in adult zebrafish. In addition, serum alanine aminotransferase activity was significantly elevated after ethanol treatment. Histological analysis revealed steatosis and hepatocyte ballooning phenotype. Gene expression analysis using quantitative real-time PCR suggested that ethanol treatment induced inflammation, apoptosis, and fibrosis. In addition, we found significant increases in gene expression involved in glucose and lipid metabolism as well as mitochondrial biogenesis and function. Importantly, expression of genes involved in oxidative and endoplasmic reticulum stress, two major stress signaling pathways underlying hepatic injury in alcoholic liver disease, were highly upregulated in the livers of adult zebrafish after chronic ethanol treatment. In conclusion, we found that 4 weeks of low dose ethanol exposure leads to typical ethanol-induced liver disease, with pathological and gene expression patterns.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Ethanol; Hepatic injury; Liver; Steatosis; Zebrafish

Mesh:

Substances:

Year:  2019        PMID: 31387182      PMCID: PMC6686888          DOI: 10.1016/j.biopha.2019.109179

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Adult zebrafish as an in vivo drug testing model for ethanol induced acute hepatic injury.

Authors:  Ki-Hoon Park; Seok-Hyung Kim
Journal:  Biomed Pharmacother       Date:  2020-10-06       Impact factor: 6.529

2.  Glutathione S-Transferase P Influences Redox Homeostasis and Response to Drugs that Induce the Unfolded Protein Response in Zebrafish.

Authors:  Leilei Zhang; Seok-Hyung Kim; Ki-Hoon Park; Ye Zhi-Wei; Zhang Jie; Danyelle M Townsend; Kenneth D Tew
Journal:  J Pharmacol Exp Ther       Date:  2021-01-29       Impact factor: 4.030

3.  Multi-omics analyses of early liver injury reveals cell-type-specific transcriptional and epigenomic shift.

Authors:  Maciej Migdał; Eugeniusz Tralle; Karim Abu Nahia; Łukasz Bugajski; Katarzyna Zofia Kędzierska; Filip Garbicz; Katarzyna Piwocka; Cecilia Lanny Winata; Michał Pawlak
Journal:  BMC Genomics       Date:  2021-12-18       Impact factor: 3.969

Review 4.  Advancements in the Alcohol-Associated Liver Disease Model.

Authors:  Lin Zhu; Hai-Di Li; Jie-Jie Xu; Juan-Juan Li; Miao Cheng; Xiao-Ming Meng; Cheng Huang; Jun Li
Journal:  Biomolecules       Date:  2022-07-27

Review 5.  Using Zebrafish as a Disease Model to Study Fibrotic Disease.

Authors:  Xixin Wang; Daniëlle Copmans; Peter A M de Witte
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 6.  Macrophages in Zebrafish Models of Liver Diseases.

Authors:  Arkadi Shwartz; Wolfram Goessling; Chunyue Yin
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.